$59.88▾ 0.80%
End-of-day close · 2026-09-01
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
More coming: dilution / share-count creep.
✦ The read
Ionis Pharmaceuticals, Inc.'s earnings-quality signal is not available yet.
Key numbers
Recent news
Sentiment · last 30 days7 articles
1 bullish5 neutral1 bearish
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook
Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?